London South East | The UK's favourite investor portal.

In the short term, our technology is going to be integrated with a wide range of techniques, it’s probably worth mentioning some of those, particularly in terms of chromatography. That is preparative flash chromatography, liquid chromatography and also think layer chromatography but also in capillary electrophoresis and we’re particularly interested in online reaction monitoring. All those techniques are becoming increasingly popular to hyphenate with mass spec especially as target compounds are becoming more complex and by that, I mean targets such as peptides, small proteins, lipids and indeed a range of many other metabolites. This is going to be done through partnerships across many geographies; Europe, North America and Asia, and that’s both through OEM’s and also through value-added distributors who don’t currently don’t have mass spectrometry as part of their offering and want to partner with someone to offer seamless integration with mass spec. Our longer-term goal is at line and on-line bioprocessing particularly in process development and then onto full scale biologic manufacture. Ultimately, our goal is to apply of mass spec expertise to point of need diagnostics but that’s something we can talk about on a later call. Q3: Now, you talk about realigning the primary focus of the company on applications in the growing biopharma market, can you tell us how you intend to go about this and why? A3: So, ultimately what Microsaic’s is going to be doing is to break our products seamlessly into a bioprocessing workflow, the biochemical analysis needs are very very different to what you would expect in a small molecule environment, small molecule production. Much more powerful analysis is needed in bioprocessing, but the trouble is that often means taking the sample to a centralised lab, now, talking to our end-users, we understand that this has created quite a few bottlenecks, those can range from days and we’ve been told even as much as 3 weeks, that causes some considerable delay in completing production runs and over the course of a year. We believe our planned investment in property development is going to bring an unrivalled ease of use for the line operator and that coupled with powerful data, real-time and software analytics. Q4: Microsaic has a strong IP portfolio, is this something that can be commercialised further? A4: Yes, so we hold over 60 patents in our core technology and we’re making continued investments in ease of use hardware and software, increased mass range, sensitivity, data analytics as I’ve said, and this is going to have an appeal to really any current or future market partner. It’s also worth noting we also have a concept triple quad and this is interesting really, not only to end users but to other instrumentation providers. Q5: So, what does your strategy as a group look like for the next 12

Microsaic Systems PLC Q&A: FY Results for the year ended 31st December 2017 (LON:MSYS) Posted by: Amilia Stone 7th March 2018 Microsaic Systems PLC (LON:MSYS) Chief Executive Officer Glenn Tracey caught up with ************* for an exclusive interview to discuss their full year results for the year ended 31 December 2017 Q1: Glenn, you released full year results this morning, can you talk us through the highlights? A1: So, I think the first point since I was become Chief Executive in September 2017, we’ve been very busy refocussing and effectively launching the business. We strengthened the Board with an addition of an experienced and successful businessman, Peter Grant and he’s the Non-Executive Chairman and we put into place a clear 5-year business strategy. Another point is that we’ve got a capable and experienced management team working with me fully aligned and we’re working hard to deliver the strategy. I’ll tell you Microsaic’s key strengths is that we’ve got a very strong IP portfolio and we’ve got very good experience of the commercialised footprint. What we’ve done is put in place a pragmatic R&D pipeline over the next 5 years and that’s targeted towards future market growth, both in small and large molecule detection. One of the other points we raised is that our resources though are focussed on bringing to market technologies in high growth market particularly in biopharma and they’re in bioprocessing. As I’ve mentioned to you before, we are very pleased to say that progress is being made with one of the foremost companies in scientific instrumentation in bioprocessing. and in December, we completed a technical feasibility stage, we took the project forward into the technical integration phase. In terms of the financials, these are in line with expectation, as expected revenues were low as we refocussed the business on the new strategy, but we did reduce costs by £600,000 and we improved the bottom line results by about £500,000. I would say that we are encouraged with progress in forming new potential partnerships and we think those will lead to modest growth in revenues particularly towards the second half of 2018. Q2: So, how do you see the business growing in the short and longer term? A2: Well, I think our approach is to form long-term collaboration with OEM partners where our products are integrated into their offering, by doing so we leverage their existing commercial position in getting to market. Now, it does take time to establish these partnerships and complete the integration but very much in the longer term, we’ll benefit from their in-depth end-user knowledge and their channel, if you like, with the end user. In the short term, our technology is going to be integrated with a wide range of techniques, it’s probably worth mentioning some of those, part

such as on-line desalting, which allows for the purification of biomolecules in real time. Key Financials for the year ended 31 December 2017 In June 2017 the Company advised that conditions in our traditional small molecule markets continued to be challenging, and as a result, our H1 revenues were significantly reduced compared with H1 2016. In H2 these conditions continued, with some improvement in sales over H1 but, as expected, full year revenues at �342,514 were substantially lower than 2016 (�851,180). The challenge of achieving growth in our traditional markets illustrates why we have shifted our strategy and development emphasis onto new market sectors, particularly in bioprocessing, where we believe there are significant commercial opportunities in the medium to long term. The Board mitigated the impact of the fall in revenues by reducing overheads, ensuring that the cash position at 31 December 2017 was in line with market expectations at the time of the 2016 fundraise, whilst at the same time maintaining R&D capacity. Overheads in 2017 were �3,049,611, �616,704 below 2016 and, as a result, EBITDA at -�2,754,284 (2016: -�3,267,408), loss before tax at �2,888,482 (2016: �3,405,804) and cash at �3,182,176 (2016: �5,728,544) were all broadly in line with the Board's expectations. Glenn Tracey, CEO, commented: "The results for the year were in line with the Board's previous expectations and illustrate why we have shifted our strategy and development emphasis onto new market sectors, particularly the very substantial market for manufacturing biopharmaceuticals. We have been pleased with the progress we have made in this area, particularly with the collaboration with one of the foremost players in the global market for scientific instrumentation. We were also pleased to have completed development of our latest miniaturised mass spectrometer, the 4500 MiD�, which has been designed to be highly robust and have a greater mass range for the detection of larger molecules." Peter Grant, Chairman, commented: "Since joining in January this year, I have been impressed with management's clear vision and strategy supported by a unique patented technology, many years of in-field experience and a pragmatic development programme focussed on meeting unmet market needs and creating new market opportunities. The Company has developed its focus on the growing and very substantial market for manufacturing biopharmaceuticals, where its products have the potential to support significant enhancements in efficiency and quality assurance. The primary approach to market is through strategic collaborations with Original Equipment Manufacturers and the Directors were delighted that the collaboration with one of the foremost players in the global market for scientific instrumentation was extended into a second phase of integration, ahe

Microsaic Systems Final Results RNS Number : 6101G Microsaic Systems plc 05 March 2018 5 March 2018 Microsaic Systems plc ("Microsaic", "Microsaic Systems" or the "Company") Final Results for the year ended 31 December 2017 Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry instruments, announces its audited financial results for the year ended 31 December 2017. The Company's Annual Report is included at the end of this announcement. Corporate Highlights � Significant progress in realigning the primary focus of the Company on applications in the growing biopharma market; � During the year, successfully completed a technical feasibility phase with one of the foremost players in the global market for scientific instrumentation in a bioprocessing application and moving this into technical integration, ahead of a potential commercialisation phase; � Collaborations with UK and US leaders in bioprocessing science and technology, which will inform further OEM discussions and wider application opportunities; � Completion of development of the 4500 MiD�, with extended mass range specifically designed for peptide and small protein detection, as the current market moves into biological synthesis; � Memorandum of Understanding signed to further extend the Company's outsourced manufacturing to increase capacity and focus future investments on product innovation; � Cost reduction programme implemented in Q1, reducing non-R&D headcount and leading to a reduction in operating expenses of �616,704 compared with 2016; and � Board strengthened with the appointment of Glenn Tracey CEO in September 2017 and Peter Grant as Non-Executive Chairman in January 2018. Strategic Progress During 2017, significant progress has been made in realigning the primary focus of the Company on applications in the growing biopharma market. In April we signed an amended agreement with one of the foremost players in the global market for scientific instrumentation. Following the successful completion of phase one, we signed a further extension to our collaboration in December. This second phase is expected to be completed in H2 2018, and our goal is to follow this with full phase three product development. This alone would represent a major commercial opportunity for the Company. During 2017, we have also continued to develop relationships with other partners to add further sales opportunities in the biopharma market. The Company has a strong product development programme aimed at supporting its bioprocessing applications and maintaining its leading position in miniaturised mass spectrometer detection instruments and technologies. Enhancements currently in the pipeline will further extend the mass range for biologics detection, and introduce new capabilities, such as o

3 years on, and so maybe ready for a partner??? GLA;-) 29/9/17 Interim Resilts The Company has also developed a working prototype of a miniaturised "triple quadrupole" instrument, and is welcoming interest from partners for further product development and channels to market for this technology, in life science applications. May 2017 Shrinking The Triple Quadrupole Mass Spectrometer Instrumentation: Researchers develop the first miniature analyzer for mass spec’s quantitation workhorse The first miniature triple-quadrupole mass analyzer is not much longer than a pencil. To uncover the molecular composition of samples outside the lab, researchers have been shrinking mass spectrometers to make them portable. Various mass analyzers—the components of the spectrometer that sort molecular fragments and send them into the detector—have already been miniaturized, including ion traps and single quadrupoles. But triple quadrupoles, the mass analyzers of choice for most quantitative mass spec applications, have not been miniaturized—until now. A team at Microsaic Systems, in Woking, England, has developed the first mini triple-quadrupole mass analyzer (Anal. Chem. 2015, DOI: 10.1021/acs.analchem.5b00311). The work “marks important progress in mass spec miniaturization,” says R. Graham Cooks, a chemistry professor at Purdue University. “Almost all previous miniature mass spectrometers have used ion traps.” “The mass spectrometer for targeted compound quantitation is the triple quad, whether the application is environmental monitoring, food safety, clinical analysis, or whatever,” says Richard A. Yost, a chemistry professor at the University of Florida. “This is really the first commercial attempt to develop a practical small-sized and potentially field-deployable triple-quad platform.” The overall mass analyzer is about 9.5 inches long, about one-quarter of the size of those used in conventional triple-quadrupole instruments, according to Steven Wright, the Microsaic scientist who led the development. The researchers demonstrated the analyzer’s abilities by coupling it to a liquid chromatograph and by using it to perform both single-stage and tandem mass spectrometry. Microsaic wants to use the mini analyzer for field applications such as food analysis, including the detection of pesticide residues on apples. “We’ve shown that we can detect pesticides at 10 ppb,” a desirable level of detection in pesticide monitoring, Wright says. But don’t expect to see a commercial instrument just yet. “There’s a great deal of system engineering to do,” Wright explains. “We have the core of the system. The physics works, and we’ve got the performance, but now we have to build a system around it.”

Latest Share Chat

Member Info for Moneymunch

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)